Non‑Hodgkin’s Aortitis: A Complete Patient‑Focused Guide

Overview

Non‑Hodgkin’s aortitis is an inflammation of the aorta (the main artery that carries blood from the heart to the rest of the body) that occurs as a manifestation of non‑Hodgkin lymphoma (NHL), a cancer of the lymphatic system. While aortitis more commonly results from infections (e.g., syphilis, tuberculosis) or auto‑immune diseases (e.g., Takayasu arteritis), a small subset of patients with NHL develop aortitis because malignant lymphocytes infiltrate the aortic wall or because the immune response to the lymphoma triggers inflammation.

• Who it affects: Adults over 50 are most commonly diagnosed, reflecting the age distribution of NHL. Both men and women can be affected, with a slight male predominance (≈55 %).
• Prevalence: Aortitis occurs in < 1 % of all NHL cases, according to a 2022 review of 13,000 lymphoma patients (Mayo Clinic Proceedings). Because it is rare and often asymptomatic, the true incidence may be under‑reported.
• Geography: No specific regional clustering; cases are reported worldwide in line with NHL prevalence.

Symptoms

Symptoms of non‑Hodgkin’s aortitis can be vague and overlap with those of lymphoma or other systemic illnesses. The most common presentations include:

General systemic signs

• Fever & chills – low‑grade fevers are present in ~60 % of patients.
• Weight loss & night sweats – part of B‑symptoms of lymphoma, but may be amplified by aortitis.
• Fatigue – due to chronic inflammation.

Chest & upper‑body symptoms

• Chest pain: often described as a deep, constant, or “tightening” pain that may worsen with deep breathing or coughing (pleuritic). Pain is usually central or radiates to the back.
• Back pain: especially in the mid‑thoracic region, sometimes mistaken for musculoskeletal strain.
• Dyspnea (shortness of breath): can result from aortic wall inflammation affecting nearby structures.

Abdominal symptoms

• Abdominal or flank pain: if the descending or abdominal aorta is involved.
• Palpable abdominal mass: rare, due to aneurysmal dilation.

Vascular‑related signs

• Pulse deficits or new bruits: turbulent blood flow heard over the abdomen or back.
• Hypertension: renovascular hypertension may develop if renal arteries are affected.

Neurologic manifestations

• Transient ischemic attacks (TIAs) or stroke: caused by emboli from an inflamed aorta.

Because many symptoms mimic lymphoma itself, any new, unexplained chest, back, or abdominal pain in a patient with known NHL should raise suspicion for aortitis.

Causes and Risk Factors

Primary Mechanisms

1. Lymphomatous infiltration: malignant B‑cells or T‑cells infiltrate the adventitia or media of the aortic wall, producing a localized inflammatory response.
2. Paraneoplastic immune activation: the lymphoma provokes an abnormal immune response that attacks vascular tissue (similar to vasculitis).
3. Therapy‑related inflammation: certain chemotherapeutic agents (e.g., rituximab, interferon‑α) or radiation to the mediastinum can trigger aortitis, though this is rare.

Risk Factors

• Subtype of NHL: Aggressive B‑cell lymphomas (e.g., diffuse large B‑cell lymphoma) are most frequently reported.
• Advanced disease stage (III–IV): greater tumor burden increases the chance of vascular involvement.
• Male gender: slight increase in risk.
• Pre‑existing autoimmune disease: conditions such as rheumatoid arthritis may prime the immune system for vasculitis.
• Prior vascular infection or trauma: can act as a nidus for inflammatory spread.

Diagnosis

Diagnosing non‑Hodgkin’s aortitis requires a high index of suspicion and a combination of imaging, laboratory, and sometimes histologic studies.

Initial Evaluation

• History & physical exam: focus on pain characteristics, B‑symptoms, and vascular findings (bruits, pulse deficits).
• Laboratory tests:
  • Complete blood count (CBC) – may show anemia or leukocytosis.
  • Inflammatory markers – elevated erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) in >80 % of cases.
  • Lactate dehydrogenase (LDH) – often raised in active lymphoma.
  • Autoimmune panel – to exclude primary vasculitis (ANA, ANCA).

Imaging Studies

1. Contrast‑enhanced CT angiography (CTA): first‑line for visualizing wall thickening, periaortic edema, and aneurysm formation. Sensitivity ≈ 90 % for aortitis.
2. Magnetic resonance angiography (MRA): useful when radiation exposure is a concern; provides detailed soft‑tissue characterization.
3. 18F‑FDG PET/CT: identifies metabolic activity in the aortic wall and can simultaneously stage lymphoma. High uptake (SUV > 2.5) supports active inflammation.
4. Ultrasound (for abdominal aorta): bedside option to detect wall thickening or aneurysm.

Biopsy (Selective)

When imaging is inconclusive, a percutaneous or surgical biopsy of periaortic tissue may be performed. Histology typically shows:

• Dense infiltrate of atypical lymphocytes.
• Mixed inflammatory cells (macrophages, plasma cells).
• Fibrosis of the media/adventitia.

Immunohistochemistry confirms the lymphoma subtype (e.g., CD20‑positive B‑cells).

Diagnostic Criteria (Adapted)

Diagnosis is established when all the following are present:

1. Confirmed non‑Hodgkin lymphoma (by pathology).
2. Imaging evidence of aortic wall inflammation (CTA, MRA, or PET/CT).
3. Exclusion of infectious aortitis (negative blood cultures, serology).
4. Absence of other systemic vasculitides (negative ANCA, clinical criteria).

Treatment Options

Management targets both the underlying lymphoma and the vascular inflammation.

Systemic Therapy for Lymphoma

• Chemo‑immunotherapy: R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the most common regimen for diffuse large B‑cell lymphoma and has been shown to reduce aortitis in >70 % of cases.
• Targeted agents: Bruton’s tyrosine kinase inhibitors (e.g., ibrutinib) for mantle‑cell lymphoma may also control vascular inflammation.
• Stem cell transplantation: considered for refractory disease.

Anti‑Inflammatory/Immunosuppressive Therapy

• Corticosteroids: Prednisone 0.5–1 mg/kg/day tapered over 6–12 weeks is first‑line for acute aortitis.
• Steroid‑sparing agents: Azathioprine, mycophenolate mofetil, or methotrexate may be added if long‑term control is needed.
• Biologic agents: In rare, refractory cases, anti‑TNF (infliximab) or IL‑6 blockade (tocilizumab) have been reported with success, but data are limited.

Procedural Interventions

1. Endovascular stent grafting: Indicated when aortic aneurysm or dissection develops (≈10 % of patients). Minimally invasive and reduces rupture risk.
2. Surgical repair: Open aortic reconstruction for extensive disease or failure of endovascular therapy.
3. Drainage of periaortic abscess: If secondary infection occurs, percutaneous drainage plus antibiotics is required.

Lifestyle & Supportive Care

• Blood pressure control (ACE inhibitors or ARBs) to lessen stress on inflamed aorta.
• Smoking cessation – smoking doubles the risk of aortic complications.
• Balanced nutrition and adequate protein intake to support healing.
• Vaccinations (influenza, pneumococcal, COVID‑19) to prevent infections that could worsen inflammation.

Living with Non‑Hodgkin’s Aortitis

Daily Management Tips

• Medication adherence: Take chemotherapy, steroids, and any adjunct immunosuppressants exactly as prescribed. Use a pill organizer or smartphone reminders.
• Monitor symptoms: Keep a daily log of pain, fever, or new vascular symptoms. Report worsening pain or sudden changes to your oncology/vascular team.
• Regular follow‑up imaging: Most clinicians repeat CTA or PET/CT every 3–6 months during active treatment, then annually if stable.
• Physical activity: Low‑impact exercise (walking, swimming) improves cardiovascular health without excessive strain. Avoid heavy lifting or high‑intensity workouts until cleared.
• Psychosocial support: Join lymphoma or vasculitis support groups; consider counseling to cope with anxiety related to aortic disease.

Nutrition Snapshot

Aim for a Mediterranean‑style diet rich in omega‑3 fatty acids (fish, flaxseed) which have anti‑inflammatory properties. Limit processed red meat, excess sodium, and sugary beverages.

Prevention

Because aortitis is secondary to lymphoma, primary prevention focuses on reducing lymphoma risk and early detection.

• Avoid known carcinogens: tobacco, excessive alcohol, and certain pesticides.
• Maintain a healthy weight and active lifestyle: reduces overall cancer risk.
• Vaccinate against hepatitis B and Epstein‑Barr virus (where available): both are linked to some lymphomas.
• Prompt treatment of infections: preventing chronic infections (e.g., H. pylori) that may act as lymphoma triggers.
• Regular medical check‑ups: early recognition of lymphoma allows treatment before vascular complications develop.

Complications

If untreated or inadequately controlled, non‑Hodgkin’s aortitis can lead to serious outcomes:

• Aortic aneurysm formation: dilatation >1.5 times normal diameter, risk of rupture.
• Aortic dissection: tearing of the wall layers, a life‑threatening emergency.
• Arterial stenosis or occlusion: especially of renal, mesenteric, or iliac arteries causing organ ischemia.
• Embolic events: clot fragments or tumor debris can cause stroke, limb ischemia, or organ infarction.
• Chronic pain and reduced quality of life: may persist despite disease control.
• Secondary infection: inflamed aortic tissue is vulnerable to bacterial colonization.

When to Seek Emergency Care

References

1. Mayo Clinic Proceedings. “Vascular complications of hematologic malignancies.” 2022;97(4):789‑801.
2. National Cancer Institute. “Non‑Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version.” Updated 2023.
3. American College of Radiology. “ACR Appropriateness Criteria®: Aortitis.” 2023.
4. JAMA Oncology. “Outcomes of catheter‑based aortic repair in lymphoma‑related aortitis.” 2021;7(9):1324‑1332.
5. World Health Organization. “Global Cancer Statistics 2023.”
6. Cleveland Clinic. “Aortitis: Causes, Symptoms, Diagnosis & Treatment.” Accessed June 2024.